10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

Inclusion Criteria:

• Early Breast Cancer patients
• Postmenopausal Status
• patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion Criteria:

• Advanced Breast Cancer patients(stage iii, iv)
• Patients who are hard to be analysed by limitation of chart record according to investigators discretion
• patients who already have been registered in this study